Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas Journal Article

   


Authors: Nayak, L.; de Groot, J.; Wefel, J. S.; Cloughesy, T. F.; Lieberman, F.; Chang, S. M.; Omuro, A.; Drappatz, J.; Batchelor, T. T.; DeAngelis, L. M.; Gilbert, M. R.; Aldape, K. D.; Yung, A. W. K.; Fisher, J.; Ye, X.; Chen, A.; Grossman, S.; Prados, M.; Wen, P. Y.
Article Title: Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas
Abstract: Anti-vascular endothelial growth factor (VEGF) therapy has shown promise in the treatment of high-grade gliomas (HGG). Aflibercept is a recombinant human fusion protein that acts as a soluble decoy receptor for VEGF-A, VEGF-B and placental growth factor, depleting circulating levels of these growth factors. The Adult Brain Tumor Consortium conducted a phase I trial of aflibercept and temozolomide (TMZ) in patients with newly diagnosed HGG with 2 dose levels and a 3+3 design. Three arms using aflibercept were examined; with radiation and concomitant temozolomide; with adjuvant temozolomide using the 5/28 regimen; and with adjuvant temozolomide using the 21/28 day regimen. Fifty-nine patients were enrolled, 21 in arm 1, 20 in arm 2 and 18 in arm 3. Median age was 56 years (24–69); median KPS 90 (60–100). The maximum tolerated dose (MTD) of aflibercept for all 3 arms was 4 mg/kg every 2 weeks. Dose limiting toxicities at the MTD were: Arm 1: 0/21 patients; Arm 2: 2/20 patients (G3 deep vein thrombosis, G4 neutropenia; Arm 3: 3/18 patients) (G4 biopsy-confirmed thrombotic microangiopathy, G3 rash, G4 thrombocytopenia). The median number of cycles of aflibercept was 5 (range, 1–16). All patients stopped treatment; 28 (47%) for disease progression, 21 (36%) for toxicities, 8 (14%) for other reasons, and 2 (3%) patients completed the full treatment course. This study met its primary endpoint and the MTD of aflibercept with radiation and concomitant and adjuvant temozolomide is 4 mg/kg every 2 weeks. © 2017, Springer Science+Business Media New York.
Keywords: temozolomide; aflibercept; dose-dense; vegf trap; newly diagnosed glioblastoma
Journal Title: Journal of Neuro-Oncology
Volume: 132
Issue: 1
ISSN: 0167-594X
Publisher: Springer  
Date Published: 2017-03-01
Start Page: 181
End Page: 188
Language: English
DOI: 10.1007/s11060-016-2357-9
PROVIDER: scopus
PUBMED: 28116649
PMCID: PMC5588922
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85010812444&doi=10.1007%2fs11060-016-2357-9&partnerID=40&md5=c680d14373f568c6fc5119b6e221089f
Notes: Article -- Export Date: 4 April 2017 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Lisa De Angelis
    576 De Angelis
  2. Antonio Marcilio Padula Omuro
    204 Omuro
Related MSK Work